| Year |
Citation |
Score |
| 2024 |
Thatikonda V, Lyu H, Jurado S, Kostyrko K, Bristow CA, Albrecht C, Alpar D, Arnhof H, Bergner O, Bosch K, Feng N, Gao S, Gerlach D, Gmachl M, Hinkel M, ... ... Heffernan TP, et al. Co-targeting SOS1 enhances the antitumor effects of KRAS inhibitors by addressing intrinsic and acquired resistance. Nature Cancer. PMID 39103541 DOI: 10.1038/s43018-024-00800-6 |
0.306 |
|
| 2024 |
Dilly J, Hoffman MT, Abbassi L, Li Z, Paradiso F, Parent BD, Hennessey CJ, Jordan AC, Morgado M, Dasgupta S, Uribe GA, Yang A, Kapner KS, Hambitzer FP, Qiang L, ... ... Heffernan TP, et al. Mechanisms of resistance to oncogenic KRAS inhibition in pancreatic cancer. Cancer Discovery. PMID 38975874 DOI: 10.1158/2159-8290.CD-24-0177 |
0.331 |
|
| 2024 |
Ho IL, Li CY, Wang F, Zhao L, Liu J, Yen EY, Dyke CA, Shah R, Liu Z, Çetin AO, Chu Y, Citron F, Attanasio S, Corti D, Darbaniyan F, ... ... Heffernan T, et al. Clonal dominance defines metastatic dissemination in pancreatic cancer. Science Advances. 10: eadd9342. PMID 38478609 DOI: 10.1126/sciadv.add9342 |
0.329 |
|
| 2024 |
Pilie PG, Giuliani V, Wang WL, McGrail DJ, Bristow CA, Ngoi NYL, Kyewalabye K, Wani KM, Le H, Campbell E, Sánchez NS, Yang D, Gheeya JS, Goswamy RV, Holla V, ... ... Heffernan TP, et al. Ataxia-Telangiectasia Mutated (ATM) loss of function displays variant and tissue-specific differences across tumor types. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 38416404 DOI: 10.1158/1078-0432.CCR-23-1763 |
0.304 |
|
| 2023 |
Perelli L, Zhang L, Mangiameli S, Russell AJC, Giannese F, Peng F, Carbone F, Le C, Khan H, Citron F, Soeung M, Lam TNA, Lundgren S, Zhu C, Catania D, ... ... Heffernan TP, et al. Evolutionary fingerprints of EMT in pancreatic cancers. Biorxiv : the Preprint Server For Biology. PMID 37786705 DOI: 10.1101/2023.09.18.558231 |
0.347 |
|
| 2023 |
Mahadevan KK, McAndrews KM, LeBleu VS, Yang S, Lyu H, Li B, Sockwell AM, Kirtley ML, Morse SJ, Moreno Diaz BA, Kim MP, Feng N, Lopez AM, Guerrero PA, Paradiso F, ... ... Heffernan TP, et al. KRAS inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8 T cells. Cancer Cell. PMID 37625401 DOI: 10.1016/j.ccell.2023.07.002 |
0.309 |
|
| 2023 |
Mahadevan KK, McAndrews KM, LeBleu VS, Yang S, Lyu H, Li B, Sockwell AM, Kirtley ML, Morse SJ, Moreno Diaz BA, Kim MP, Feng N, Lopez AM, Guerrero PA, Sugimoto H, ... ... Heffernan TP, et al. Oncogenic Kras specific non-covalent inhibitor reprograms tumor microenvironment to prevent and reverse early pre-neoplastic pancreatic lesions and in combination with immunotherapy regresses advanced PDAC in a CD8 T cells dependent manner. Biorxiv : the Preprint Server For Biology. PMID 36824971 DOI: 10.1101/2023.02.15.528757 |
0.347 |
|
| 2023 |
Thatikonda V, Lu H, Jurado S, Kostyrko K, Bristow CA, Bosch K, Feng N, Gao S, Gerlach D, Gmachl M, Lieb S, Jeschko A, Machado AA, Marszalek ED, Mahendra M, ... ... Heffernan TP, et al. Combined KRAS and SOS1 inhibition enhances and extends the anti-tumor response in KRAS -driven cancers by addressing intrinsic and acquired resistance. Biorxiv : the Preprint Server For Biology. PMID 36747713 DOI: 10.1101/2023.01.23.525210 |
0.366 |
|
| 2021 |
Redwood AB, Zhang X, Seth SB, Ge Z, Bindeman WE, Zhou X, Sinha VC, Heffernan TP, Piwnica-Worms H. The cytosolic iron-sulfur cluster assembly (CIA) pathway is required for replication stress tolerance of cancer cells to Chk1 and ATR inhibitors. Npj Breast Cancer. 7: 152. PMID 34857765 DOI: 10.1038/s41523-021-00353-2 |
0.33 |
|
| 2021 |
Evans KW, Yuca E, Scott SS, Zhao M, Paez Arango N, Cruz Pico CX, Saridogan T, Shariati M, Class CA, Bristow CA, Vellano CP, Zheng X, Gonzalez-Angulo AM, Su X, Tapia C, ... ... Heffernan TP, et al. Oxidative phosphorylation is a metabolic vulnerability in chemotherapy-resistant triple negative breast cancer. Cancer Research. PMID 34518211 DOI: 10.1158/0008-5472.CAN-20-3242 |
0.377 |
|
| 2021 |
Giuliani V, Miller MA, Liu CY, Hartono SR, Class CA, Bristow CA, Suzuki E, Sanz LA, Gao G, Gay JP, Feng N, Rose JL, Tomihara H, Daniele JR, Peoples MD, ... ... Heffernan TP, et al. PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma. Nature Communications. 12: 4626. PMID 34330913 DOI: 10.1038/s41467-021-24798-y |
0.323 |
|
| 2021 |
Yan L, Tu B, Yao J, Gong J, Carugo A, Bristow CA, Wang Q, Zhu C, Dai B, Kang Y, Han L, Feng N, Jin Y, Fleming J, Heffernan TP, et al. Targeting glucose metabolism sensitizes pancreatic cancer to MEK inhibition. Cancer Research. PMID 34117030 DOI: 10.1158/0008-5472.CAN-20-3792 |
0.369 |
|
| 2021 |
Shariati M, Evans KW, Zheng X, Bristow CA, Ng PK, Rizvi YQ, Tapia C, Yang F, Carugo A, Heffernan TP, Peoples MD, Tripathy D, Meric-Bernstam F. Combined inhibition of DDR1 and CDK4/6 induces synergistic effects in ER-positive, HER2-negative breast cancer with PIK3CA/AKT1 mutations. Oncogene. PMID 34108622 DOI: 10.1038/s41388-021-01819-0 |
0.35 |
|
| 2021 |
Inoue A, Robinson FS, Minelli R, Tomihara H, Rizi BS, Rose JL, Kodama T, Srinivasan S, Harris AL, Zuniga AM, Mullinax RA, Ma X, Seth S, Daniele JR, Peoples MD, ... ... Heffernan TP, et al. Sequential administration of XPO1 and ATR inhibitors enhances therapeutic response in TP53-mutated colorectal cancer. Gastroenterology. PMID 33745946 DOI: 10.1053/j.gastro.2021.03.022 |
0.335 |
|
| 2020 |
Punt S, Malu S, McKenzie JA, Manrique SZ, Doorduijn EM, Mbofung RM, Williams L, Silverman DA, Ashkin EL, Dominguez AL, Wang Z, Chen JQ, Maiti SN, Tieu TN, Liu C, ... ... Heffernan TP, et al. Aurora kinase inhibition sensitizes melanoma cells to T-cell-mediated cytotoxicity. Cancer Immunology, Immunotherapy : Cii. PMID 33123754 DOI: 10.1007/s00262-020-02748-9 |
0.374 |
|
| 2020 |
Powell RT, Redwood A, Liu X, Guo L, Cai S, Zhou X, Tu Y, Zhang X, Qi Y, Jiang Y, Echeverria G, Feng N, Ma X, Giuliani V, Marszalek JR, ... Heffernan TP, et al. Pharmacologic profiling of patient-derived xenograft models of primary treatment-naïve triple-negative breast cancer. Scientific Reports. 10: 17899. PMID 33087803 DOI: 10.1038/s41598-020-74882-4 |
0.322 |
|
| 2020 |
Sun Y, Meyers BA, Czako B, Leonard P, Mseeh F, Harris AL, Wu Q, Johnson S, Parker CA, Cross JB, Di Francesco ME, Bivona BJ, Bristow CA, Burke JP, Carrillo CC, ... ... Heffernan TP, et al. Allosteric SHP2 inhibitor IACS-13909 overcomes EGFR-dependent and EGFR-independent resistance mechanisms towards osimertinib. Cancer Research. PMID 32928921 DOI: 10.1158/0008-5472.Can-20-1634 |
0.429 |
|
| 2020 |
Hofmann MH, Gmachl M, Ramharter J, Savarese F, Gerlach D, Marszalek JR, Sanderson MP, Kessler D, Trapani F, Arnhof H, Rumpel K, Botesteanu DA, Ettmayer P, Gerstberger T, Kofink C, ... ... Heffernan TP, et al. BI-3406, a potent and selective SOS1::KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition. Cancer Discovery. PMID 32816843 DOI: 10.1158/2159-8290.Cd-20-0142 |
0.447 |
|
| 2020 |
Czako B, Marszalek JR, Burke JP, Mandal PK, Leonard PG, Cross JB, Mseeh F, Jiang Y, Chang EQ, Suzuki E, Jeffrey KJ, Feng N, Gera S, Harris AL, Liu Z, ... ... Heffernan TP, et al. Discovery of IACS-9439, a potent, exquisitely selective and orally bioavailable inhibitor of CSF1R. Journal of Medicinal Chemistry. PMID 32787110 DOI: 10.1021/Acs.Jmedchem.0C00936 |
0.456 |
|
| 2020 |
Msaouel P, Malouf GG, Su X, Yao H, Tripathi DN, Soeung M, Gao J, Rao P, Coarfa C, Creighton CJ, Bertocchio JP, Kunnimalaiyaan S, Multani AS, Blando J, He R, ... ... Heffernan TP, et al. Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma. Cancer Cell. PMID 32359397 DOI: 10.1016/J.Ccell.2020.04.002 |
0.359 |
|
| 2020 |
Pilie PG, Gheeya JS, Kyewalabye K, Goswamy RV, Wani KM, Le H, Campbell E, Sanchez NS, Yang D, Garmezy B, Dumbrava EEI, Ahnert JR, Heffernan T, Holla V, Shaw KR, et al. Identifying functional loss of ATM gene in patients with advanced cancer. Journal of Clinical Oncology. 38: 3629-3629. DOI: 10.1200/Jco.2020.38.15_Suppl.3629 |
0.362 |
|
| 2020 |
Konen J, Rodriguez BL, Gibson L, Minelli R, Kovacs J, Carugo A, Bristow C, Heffernan T, Gibbons DL. Abstract A43: Identifying a role for Ntrk1 in regulating immune functionality and checkpoint blockade resistance in Kras/p53 mutant lung cancer Cancer Immunology Research. 8. DOI: 10.1158/2326-6074.Tumimm18-A43 |
0.468 |
|
| 2020 |
Echeverria GV, Xu M, Shao J, Zhang X, Jeter-Jones S, Zhou X, Moulder SL, Marszalek JR, Heffernan TP, Symmans FW, Chang JT, Piwnica-Worms H. Abstract GS4-02: Investigating genomic and phenotypic evolution of triple negative breast cancer chemoresistance and metastasis in patient-derived xenografts Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Gs4-02 |
0.478 |
|
| 2020 |
Seth S, Huo L, Rauch GM, Adrada B, Piwnica-Worms H, Lim B, Thompson AM, Mittendorf EA, Heffernan T, Litton JK, Symmans WF, Draetta GF, Futreal AP, Chang JT, Moulder SL. Abstract 1497: Longitudinal response and selection under neoadjuvant systemic therapy (NAST) in triple-negative breast cancer (TNBC): Profiling results from a randomized trial (ARTEMIS; NCT02276443) Tumor Biology. DOI: 10.1158/1538-7445.Am2020-1497 |
0.304 |
|
| 2020 |
Gerlach D, Gmachl M, Ramharter J, Teh J, Fu S, Trapani F, Kessler D, Rumpel K, Botesteanu D, Ettmayer P, Arnhof H, Gerstberger T, Kofink C, Wunberg T, Vellano CP, ... Heffernan TP, et al. Abstract 1091: BI-3406 and BI 1701963: Potent and selective SOS1::KRAS inhibitors induce regressions in combination with MEK inhibitors or irinotecan Cancer Research. 80: 1091-1091. DOI: 10.1158/1538-7445.Am2020-1091 |
0.473 |
|
| 2019 |
Wu S, Gao F, Zheng S, Zhang C, Martinez-Ledesma E, Ezhilarasan R, Ding J, Li X, Feng N, Multani A, Sulman EP, Verhaak RG, de Groot JF, Heffernan TP, Yung WKA, et al. EGFR amplification induces increased DNA damage response and renders selective sensitivity to Talazoparib (PARP inhibitor) in glioblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31852834 DOI: 10.1158/1078-0432.Ccr-19-2549 |
0.411 |
|
| 2019 |
Kapoor A, Yao W, Ying H, Hua S, Liewen A, Wang Q, Zhong Y, Wu CJ, Sadanandam A, Hu B, Chang Q, Chu GC, Al-Khalil R, Jiang S, Xia H, ... ... Heffernan T, et al. Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer. Cell. 179: 1239. PMID 31730860 DOI: 10.1016/J.Cell.2019.10.037 |
0.337 |
|
| 2019 |
Manshouri R, Coyaud E, Kundu ST, Peng DH, Stratton SA, Alton K, Bajaj R, Fradette JJ, Minelli R, Peoples MD, Carugo A, Chen F, Bristow C, Kovacs JJ, Barton MC, ... Heffernan T, et al. ZEB1/NuRD complex suppresses TBC1D2b to stimulate E-cadherin internalization and promote metastasis in lung cancer. Nature Communications. 10: 5125. PMID 31719531 DOI: 10.1038/S41467-019-12832-Z |
0.38 |
|
| 2019 |
Tu B, Yao J, Ferri-Borgogno S, Zhao J, Chen S, Wang Q, Yan L, Zhou X, Zhu C, Bang S, Chang Q, Bristow CA, Kang Y, Zheng H, Wang H, ... ... Heffernan TP, et al. YAP1 oncogene is a context-specific driver for pancreatic ductal adenocarcinoma. Jci Insight. PMID 31557131 DOI: 10.1172/Jci.Insight.130811 |
0.434 |
|
| 2019 |
Inoue A, Deem AK, Kopetz S, Heffernan TP, Draetta GF, Carugo A. Current and Future Horizons of Patient-Derived Xenograft Models in Colorectal Cancer Translational Research. Cancers. 11. PMID 31500168 DOI: 10.3390/Cancers11091321 |
0.389 |
|
| 2019 |
Zhang L, Yao Y, Zhang S, Liu Y, Guo H, Ahmed M, Bell T, Zhang H, Han G, Lorence E, Badillo M, Zhou S, Sun Y, Di Francesco ME, Feng N, ... ... Heffernan T, et al. Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma. Science Translational Medicine. 11. PMID 31068440 DOI: 10.1126/Scitranslmed.Aau1167 |
0.412 |
|
| 2019 |
Echeverria GV, Ge Z, Seth S, Zhang X, Jeter-Jones S, Zhou X, Cai S, Tu Y, McCoy A, Peoples M, Sun Y, Qiu H, Chang Q, Bristow C, Carugo A, ... ... Heffernan TP, et al. Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state. Science Translational Medicine. 11. PMID 30996079 DOI: 10.1126/Scitranslmed.Aav0936 |
0.445 |
|
| 2019 |
Konen JM, Rodriguez BL, Fradette JJ, Gibson L, Davis D, Minelli R, Peoples MD, Kovacs J, Carugo A, Bristow C, Heffernan T, Gibbons DL. Ntrk1 Promotes Resistance to PD-1 Checkpoint Blockade in Mesenchymal Kras/p53 Mutant Lung Cancer. Cancers. 11. PMID 30986992 DOI: 10.3390/Cancers11040462 |
0.45 |
|
| 2019 |
Yao W, Rose JL, Wang W, Seth S, Jiang H, Taguchi A, Liu J, Yan L, Kapoor A, Hou P, Chen Z, Wang Q, Nezi L, Xu Z, Yao J, ... ... Heffernan TP, et al. Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer. Nature. PMID 30918400 DOI: 10.1038/S41586-019-1062-1 |
0.4 |
|
| 2019 |
Peng DH, Kundu ST, Fradette JJ, Diao L, Tong P, Byers LA, Wang J, Canales JR, Villalobos PA, Mino B, Yang Y, Minelli R, Peoples MD, Bristow CA, Heffernan TP, et al. ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism. Science Translational Medicine. 11. PMID 30867319 DOI: 10.1126/Scitranslmed.Aaq1238 |
0.489 |
|
| 2019 |
Carugo A, Minelli R, Sapio L, Soeung M, Carbone F, Robinson FS, Tepper J, Chen Z, Lovisa S, Svelto M, Amin S, Srinivasan S, Del Poggetto E, Loponte S, Puca F, ... ... Heffernan TP, et al. p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors. Cancer Cell. 35: 204-220.e9. PMID 30753823 DOI: 10.1016/J.Ccell.2019.01.006 |
0.422 |
|
| 2019 |
Seth S, Li CY, Ho IL, Corti D, Loponte S, Sapio L, Del Poggetto E, Yen EY, Robinson FS, Peoples M, Karpinets T, Deem AK, Kumar T, Song X, Jiang S, ... ... Heffernan TP, et al. Pre-existing Functional Heterogeneity of Tumorigenic Compartment as the Origin of Chemoresistance in Pancreatic Tumors. Cell Reports. 26: 1518-1532.e9. PMID 30726735 DOI: 10.1016/J.Celrep.2019.01.048 |
0.452 |
|
| 2019 |
Sun Y, Bandi M, Lofton T, Smith M, Bristow CA, Carugo A, Rogers N, Leonard P, Chang Q, Mullinax R, Han J, Shi X, Seth S, Meyers BA, Miller M, ... ... Heffernan TP, et al. Functional Genomics Reveals Synthetic Lethality between Phosphogluconate Dehydrogenase and Oxidative Phosphorylation. Cell Reports. 26: 469-482.e5. PMID 30625329 DOI: 10.1016/J.Celrep.2018.12.043 |
0.452 |
|
| 2019 |
Yung WKA, Wu S, Gao F, Zheng S, Ding J, Zhang C, Li X, Ezhilarasan R, Feng N, De Groot JF, Sulman EP, Heffernan T, Koul D. EGFR amplification predicted selective sensitivity to PARP inhibitors with high PARP-DNA trapping potential in human GBM. Journal of Clinical Oncology. 37: 2047-2047. DOI: 10.1200/Jco.2019.37.15_Suppl.2047 |
0.418 |
|
| 2019 |
Shariati M, Paez-Arango N, Bristow C, Evans K, Peoples, Carugo A, Heffernan T, Meric-Bernstam F. Abstract P6-18-13: Identification of optimal combination therapy partners for PI3K/Akt/mTOR pathway inhibitor in triple negative breast cancer Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-P6-18-13 |
0.434 |
|
| 2019 |
Echeverria G, Ge Z, Seth S, Jeter-Jones S, Zhang X, Zhou X, Cai S, Tu Y, McCoy A, Peoples M, Lau R, Shao J, Sun Y, Bristow C, Carugo A, ... ... Heffernan T, et al. Abstract GS5-05: Resistance to neoadjuvant chemotherapy in triple negative breast cancer mediated by a reversible drug-tolerant state Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-Gs5-05 |
0.474 |
|
| 2019 |
Pickering C, Kumar M, Bridges K, Xie T, Molkentine D, Sheth A, Yang L, Frederick M, Heffernan T, Seth S, Myers J, Skinner HD. Abstract 2925: Targeting histone acetyltransferase (HAT) function for synthetic cytotoxicity in CREBBP/EP300 mutant tumors Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-2925 |
0.36 |
|
| 2019 |
Echeverria GV, Ge Z, Seth S, Powell E, Zhang X, Jeter-Jones S, Zhou X, Jiang Y, McCoy A, Cai S, Tu Y, Peoples M, Sun Y, Qiu H, Bristow C, ... ... Heffernan TP, et al. Abstract 2901: Clonal dynamics and phenotypic evolution during chemoresistance and metastasis revealed by patient-derived xenograft models of triple negative breast cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-2901 |
0.336 |
|
| 2019 |
Seth S, Li C, Loponte S, Ho I, Corti D, Sapio L, Poggetto ED, Peoples M, Karpinets T, Robinson FS, Jiang S, Dutta P, Marszalek J, Francesco MED, Heffernan TP, et al. Abstract 2900: Dissection of clonal heterogeneity unmasks pre-existing chemoresistance and new metabolic vulnerabilities in pancreatic cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-2900 |
0.307 |
|
| 2019 |
Giuliani V, Carugo A, Miller M, Sanz L, Liu C, Bristow CA, Suzuki E, Class CA, Hartono SR, Gao G, Feng N, Vangamudi B, Marszalek JR, Kovacs J, Francesco MED, ... ... Heffernan T, et al. Abstract 277: Inhibition of protein arginine methylation alters RNA metabolism and DNA damage response providing a new therapeutic strategy in pancreatic ductal adenocarcinoma Cancer Research. 79: 277-277. DOI: 10.1158/1538-7445.Am2019-277 |
0.415 |
|
| 2019 |
Hofmann MH, Gmachl M, Ramharter J, Savarese F, Gerlach D, Marszalek JR, Sanderson MP, Trapani F, Kessler D, Rumpel K, Botesteanu D, Ettmayer P, Arnhof H, Gerstberger T, Kofink C, ... ... Heffernan TP, et al. Abstract PL06-01: Discovery of BI-3406: A potent and selective SOS1::KRAS inhibitor opens a new approach for treating KRAS-driven tumors Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-Pl06-01 |
0.5 |
|
| 2019 |
Sun Y, Meyers BA, Johnson SB, Harris AL, Czako B, Cross JB, Leonard PG, Mseeh F, Francesco MED, Parker CA, Wu Q, Bristow CA, Burke JP, Carrillo CC, Carroll CL, ... ... Heffernan TP, et al. Abstract C036: Discovery of IACS-13909, an allosteric SHP2 inhibitor that overcomes multiple mechanisms underlying osimertinib resistance Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-C036 |
0.441 |
|
| 2019 |
Shariati M, Bristow CA, Carugo A, Heffernan T, Zheng X, Peoples MD, Tripathy D, Meric-Bernstam F. Abstract B104: Combined inhibition of DDR1 and CDK4/6 induces synergistic effects in ER-positive, HER2-negative breast cancer with PIK3CA/AKT1 mutations Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-B104 |
0.45 |
|
| 2018 |
Echeverria GV, Powell E, Seth S, Ge Z, Carugo A, Bristow C, Peoples M, Robinson F, Qiu H, Shao J, Jeter-Jones SL, Zhang X, Ramamoorthy V, Cai S, Wu W, ... ... Heffernan TP, et al. High-resolution clonal mapping of multi-organ metastasis in triple negative breast cancer. Nature Communications. 9: 5079. PMID 30498242 DOI: 10.1038/S41467-018-07406-4 |
0.393 |
|
| 2018 |
Hsu JI, Dayaram T, Tovy A, De Braekeleer E, Jeong M, Wang F, Zhang J, Heffernan TP, Gera S, Kovacs JJ, Marszalek JR, Bristow C, Yan Y, Garcia-Manero G, Kantarjian H, et al. PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy. Cell Stem Cell. 23: 700-713.e6. PMID 30388424 DOI: 10.1016/J.Stem.2018.10.004 |
0.358 |
|
| 2018 |
Molina JR, Sun Y, Protopopova M, Gera S, Bandi M, Bristow C, McAfoos T, Morlacchi P, Ackroyd J, Agip AA, Al-Atrash G, Asara J, Bardenhagen J, Carrillo CC, Carroll C, ... ... Heffernan TP, et al. An inhibitor of oxidative phosphorylation exploits cancer vulnerability. Nature Medicine. PMID 29892070 DOI: 10.1038/S41591-018-0052-4 |
0.453 |
|
| 2018 |
Powell E, Shao J, Picon HM, Bristow C, Ge Z, Peoples M, Robinson F, Jeter-Jones SL, Schlosberg C, Grzeskowiak CL, Yang F, Wu Y, Wistuba I, Moulder SL, Symmans WF, ... ... Heffernan TP, et al. A functional genomic screen in vivo identifies CEACAM5 as a clinically relevant driver of breast cancer metastasis. Npj Breast Cancer. 4: 9. PMID 29736411 DOI: 10.1038/s41523-018-0062-x |
0.342 |
|
| 2018 |
Cascone T, McKenzie JA, Mbofung RM, Punt S, Wang Z, Xu C, Williams LJ, Wang Z, Bristow CA, Carugo A, Peoples MD, Li L, Karpinets T, Huang L, Malu S, ... ... Heffernan TP, et al. Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy. Cell Metabolism. PMID 29628419 DOI: 10.1016/J.Cmet.2018.02.024 |
0.467 |
|
| 2018 |
Huang L, Malu S, McKenzie JA, Andrews MC, Talukder AH, Tieu T, Karpinets TV, Haymaker C, Forget MA, Williams LJ, Wang Z, Mbofung R, Wang ZQ, Davis RE, Lo RS, ... ... Heffernan TP, et al. The RNA-binding protein MEX3B mediates resistance to cancer immunotherapy by downregulating HLA-A expression. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29496759 DOI: 10.1158/1078-0432.Ccr-17-2483 |
0.362 |
|
| 2018 |
Echeverria G, Seth S, Ge Z, Sun Y, DiFrancesco E, Lau R, Marszalek J, Moulder S, Symmans F, Heffernan T, Chang J, Piwnica-Worms H. Abstract P4-03-02: Characterizing and targeting chemoresistant subclones in patient-derived xenograft models of triple negative breast cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P4-03-02 |
0.341 |
|
| 2018 |
Seth S, Li C, Corti D, Loponte S, Ho I, Poggetto ED, Peoples M, Bristow C, Marszalek J, Heffernan T, Genovese G, Draetta G, Carugo A, Viale A. Abstract A15: Generation of clonal replica tumors to interrogate complexity of human cancer in vivo Cancer Research. 78. DOI: 10.1158/1538-7445.Mousemodels17-A15 |
0.461 |
|
| 2018 |
Genovese G, Carugo A, Minelli R, Frederick, Robinson S, Msaouel P, Heffernan T, Viale A, Tannir N, Draetta G. Abstract A03: Perturbation of proteostasis is lethal in SMARCB1-deficient tumors Cancer Research. 78. DOI: 10.1158/1538-7445.Mousemodels17-A03 |
0.473 |
|
| 2018 |
Suzuki E, Kovacs JJ, Spencer ND, Sonal S, Feng N, Harris AL, Mullinax RA, Zuniga AM, Johnson SB, Mahendra M, Khor TO, Mseeh F, Liu Z, Burke JP, Mikule K, ... ... Heffernan TP, et al. Abstract LB-124: Promoting an anti-tumor immune environment with a novel, exquisitely selective CSF1R inhibitor Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Lb-124 |
0.417 |
|
| 2018 |
Powell E, Shao J, Picon H, Bristow C, Ge Z, Grzeskowiak C, Peoples M, Robinson F, Jeter-Jones S, Schlosberg C, Yang F, Wu Y, Wistuba I, Moulder S, Symmans F, ... ... Heffernan T, et al. Abstract 5172: A functional genomic screen in vivo identifies CEACAM5 as a clinically relevant driver of breast cancer metastasis Tumor Biology. DOI: 10.1158/1538-7445.Am2018-5172 |
0.337 |
|
| 2018 |
Rose JL, Carugo A, Yao W, Seth S, Srinivasan S, Peoples M, Hart T, Heffernan T, Draetta G. Abstract 392: Reverse functional genomics: Identifying differentially regulated functional networks as predictive biomarkers of pivotal vulnerabilities in pancreatic cancer Cancer Research. 78: 392-392. DOI: 10.1158/1538-7445.Am2018-392 |
0.361 |
|
| 2018 |
Marszalek JR, Seth S, Corti D, Zhang Q, Echeverria GV, Han L, Sun Y, Molina J, Gera S, Chang E, Khor TO, Mahendra M, Feng N, McAfoos T, Giuliani V, ... ... Heffernan TP, et al. Abstract 2856: Targeting OXPHOS with IACS-010759 to eliminate standard of care resistant tumor cells Cancer Research. 78: 2856-2856. DOI: 10.1158/1538-7445.Am2018-2856 |
0.464 |
|
| 2018 |
Galan-Cobo A, Sitthideatphaiboon P, Qu X, Kovacs JJ, Poteete A, Tong P, Cho S, Gandhi VV, Skoulidis F, Wang J, Heffernan TP, Heymach JV. Abstract 2408: LKB1 and KEAP1/NRF2 pathways cooperatively promote glutamine dependence and vulnerability to glutaminase inhibitors in KRAS-mutant lung adenocarcinoma Cancer Research. 78: 2408-2408. DOI: 10.1158/1538-7445.Am2018-2408 |
0.474 |
|
| 2018 |
Echeverria GV, Seth S, Ge Z, Carugo A, Bristow C, Mundi P, Jeter-Jones S, Zhang X, Zhou X, McCoy A, Cai S, Tu Y, Sun Y, Marszalek J, Califano A, ... ... Heffernan TP, et al. Abstract 212: High-resolution barcoding in patient-derived xenografts of triple-negative breast cancer reveals reversible chemoresistance conferred by non-mutational mechanisms Cancer Research. 78: 212-212. DOI: 10.1158/1538-7445.Am2018-212 |
0.477 |
|
| 2018 |
Francesco MED, Marszalek JR, McAfoos T, Carroll CL, Kang Z, Liu G, Theroff JP, Bardenhager JP, Bandi ML, Molina JR, Gera S, Protopopova M, Sun Y, Do MKG, Feng N, ... ... Heffernan TP, et al. Abstract 1655: Discovery and development of IACS-010759, a novel inhibitor of Complex I currently in phase I studies to exploit oxidative phosphorylation dependency in acute myeloid leukemia and solid tumors Cancer Research. 78: 1655-1655. DOI: 10.1158/1538-7445.Am2018-1655 |
0.456 |
|
| 2018 |
Wu S, Gao F, Zheng S, Zhang C, Martinez-Ledesma JE, Ezhilarasan R, Ding J, Li X, Feng N, Sulman E, Verhaak R, Groot Jd, Heffernan T, Yung WKA, Koul D. Ddis-03. Egfr Amplification Induced Increased Dna Damage Response And Predicted Selective Sensitivity To Talazoparib (Parp Inhibitor) In Glioblastoma Stem-Like Cells Neuro-Oncology. 20. DOI: 10.1093/Neuonc/Noy148.282 |
0.367 |
|
| 2017 |
McKenzie JA, Mbofung RM, Malu S, Zhang M, Ashkin E, Devi S, Williams L, Tieu T, Peng W, Pradeep S, Xu C, Zorro Manrique S, Liu C, Huang L, Chen Y, ... ... Heffernan T, et al. The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy. Journal of the National Cancer Institute. PMID 29267866 DOI: 10.1093/Jnci/Djx257 |
0.432 |
|
| 2017 |
Sakellariou-Thompson D, Forget MA, Creasy C, Bernard V, Zhao L, Kim YU, Hurd MW, Uraoka N, Parra ER, Kang Y, Bristow CA, Rodriguez-Canales J, Fleming JB, Varadhachary GR, Javle M, ... ... Heffernan TP, et al. 4-1BB agonist focuses CD8(+) tumor-infiltrating T-cell growth into a distinct repertoire capable of tumor recognition in pancreatic cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28947567 DOI: 10.1158/1078-0432.Ccr-17-0831 |
0.404 |
|
| 2017 |
Mbofung RM, McKenzie JA, Malu S, Zhang M, Peng W, Liu C, Kuiatse I, Tieu T, Williams L, Devi S, Ashkin E, Xu C, Huang L, Zhang M, Talukder AH, ... ... Heffernan T, et al. HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes. Nature Communications. 8: 451. PMID 28878208 DOI: 10.1038/S41467-017-00449-Z |
0.414 |
|
| 2017 |
Li L, Karanika S, Yang G, Wang J, Park S, Broom BM, Manyam GC, Wu W, Luo Y, Basourakos S, Song JH, Gallick GE, Karantanos T, Korentzelos D, Azad AK, ... ... Heffernan T, et al. Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer. Science Signaling. 10. PMID 28536297 DOI: 10.1126/Scisignal.Aam7479 |
0.442 |
|
| 2017 |
Genovese G, Carugo A, Tepper J, Robinson FS, Li L, Svelto M, Nezi L, Corti D, Minelli R, Pettazzoni P, Gutschner T, Wu CC, Seth S, Akdemir KC, Leo E, ... ... Heffernan TP, et al. Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. Nature. PMID 28178232 DOI: 10.1038/Nature21064 |
0.424 |
|
| 2017 |
Powell E, Shao J, Picon H, Ge Z, Echeverria G, Peoples M, Bristow C, Cai S, Tu Y, McCoy A, Piwnica-Worms D, Draetta G, Edwards J, Moulder S, Symmans W, ... Heffernan T, et al. Abstract P6-01-08: Identifying metastatic drivers in patient derived xenograft models of triple negative breast cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs16-P6-01-08 |
0.402 |
|
| 2017 |
Giuliani V, Vangamudi B, Suzuki E, Miller M, Liu C, Carugo A, Bristow C, Gao G, Han J, Sun Y, Feng N, Chang E, Marszalek J, Kovacs J, Francesco MED, ... ... Heffernan T, et al. Abstract 3016: Identification of protein arginine methyltransferase 1 as novel epigenetic vulnerability in KRAS/p53 mutant PDAC primary patient models Cancer Research. 77: 3016-3016. DOI: 10.1158/1538-7445.Am2017-3016 |
0.459 |
|
| 2017 |
Wang Q, Ezhilarasan R, Goodman L, Eskilsson E, Yang J, Gumin J, Zheng S, Tang M, Jaffari M, Long L, Yoshihara K, Sun P, Heffernan T, Yung WKA, Draetta G, et al. TMOD-04. A COMPREHENSIVE GENOMIC LANDSCAPE OF GLIOMA SPHEROID CULTURES RECAPITULATES THE HETEROGENEITY OF GLIOBLASTOMA AND IDENTIFIES DNA METHYLATION PREDICTORS OF RADIOTHERAPY RESPONSE Neuro-Oncology. 19: vi255-vi255. DOI: 10.1093/Neuonc/Nox168.1043 |
0.307 |
|
| 2016 |
Carugo A, Genovese G, Seth S, Nezi L, Rose JL, Bossi D, Cicalese A, Shah PK, Viale A, Pettazzoni PF, Akdemir KC, Bristow CA, Robinson FS, Tepper J, Sanchez N, ... ... Heffernan TP, et al. In Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer. Cell Reports. PMID 27320920 DOI: 10.1016/J.Celrep.2016.05.063 |
0.462 |
|
| 2016 |
Bossi D, Cicalese A, Dellino GI, Luzi L, Riva L, D'Alesio C, Diaferia GR, Carugo A, Cavallaro E, Piccioni R, Barberis M, Mazzarol G, Testori A, Punzi S, Pallavicini I, ... ... Heffernan TP, et al. In Vivo Genetic Screens of Patient-Derived Tumors Revealed Unexpected Frailty of the Transformed Phenotype. Cancer Discovery. 6: 650-63. PMID 27179036 DOI: 10.1158/2159-8290.Cd-15-1200 |
0.407 |
|
| 2016 |
Lee MS, Helms TL, Feng N, Gay J, Chang QE, Tian F, Wu JY, Toniatti C, Heffernan TP, Powis G, Kwong LN, Kopetz S. Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models. Oncotarget. PMID 27167191 DOI: 10.18632/Oncotarget.9153 |
0.452 |
|
| 2016 |
McKenzie JA, Mbofung RM, Malu S, Amaria RN, Ashkin EL, Devi SN, Peng W, Williams LJ, Davis RE, Roszik J, Tieu TN, Heffernan T, Hwu P. Abstract B110: Topoisomerase I inhibitors enhance efficacy of immunotherapy through a p53 regulatory pathway Cancer Immunology Research. 4. DOI: 10.1158/2326-6066.Imm2016-B110 |
0.505 |
|
| 2016 |
Mbofung RM, McKenzie JA, Malu S, Liu C, Peng W, Kuiatse I, Williams L, Devi S, Wang Z, Tieu T, Heffernan T, Davis RE, Amaria R, Hwu P. Abstract B105: HSP90 inhibitor, ganetespib, enhances responses to cancer immunotherapy through increased expression of interferon response genes Cancer Immunology Research. 4. DOI: 10.1158/2326-6066.Imm2016-B105 |
0.488 |
|
| 2016 |
Carugo A, Genovese G, Seth S, Nezi L, Cicalese A, Bossi D, Rose JL, Viale A, Lanfrancone L, Heffernan TP, Draetta GF. Abstract B43: PILOT: a patient-oriented in vivo functional platform to identify new lethalities and optimize cancer treatment Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Pdx16-B43 |
0.52 |
|
| 2016 |
Yennu-Nanda VG, Hu Z, Thiele VM, Heffernan T, DiFrancesco M, Marszalek J, Deberadinis R, Davies MA. Abstract A52: Overcoming mitochondrial oxidative phosphorylation-mediated resistance to targeted therapies in melanoma Molecular Cancer Research. 14. DOI: 10.1158/1557-3125.Metca15-A52 |
0.453 |
|
| 2016 |
Echeverria G, Seth S, Moulder S, Symmans W, Chang J, Cai S, Heffernan T, Piwnica-Worms H. Abstract P3-06-04: Investigating clonal dynamics in triple negative breast cancer chemoresistance Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P3-06-04 |
0.428 |
|
| 2016 |
Powell E, Shao J, Mistry N, Yuan Y, Tieu T, Decker K, Chen H, Cai S, Do K, Heffernan T, Edwards J, Piwnica-Worms D, Piwnica-Worms H. Abstract P2-05-08: p53 deficiency enhances metastatic potential of triple negative breast cancer by promoting growth in primary and metastatic sites Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P2-05-08 |
0.32 |
|
| 2016 |
Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff M, Xu C, McKenzie J, Zhang C, Liang X, Williams L, Deng W, Chen G, Mbofung R, Lazar A, ... ... Heffernan T, et al. Abstract 4363: Loss of PTEN promotes resistance to T cell-mediated immunotherapy Cancer Research. 76: 4363-4363. DOI: 10.1158/1538-7445.Am2016-4363 |
0.469 |
|
| 2016 |
Mbofung RM, McKenzie JA, Malu S, Liu C, Williams L, Peng W, Wang Z, Tripathi S, Tieu T, Zhao S, Devi S, Kuiatse I, Ashkin E, Bailey L, Roszik J, ... ... Heffernan T, et al. Abstract 4360: Inhibition of HSP90 enhances T cell-mediated antitumor immune responses through expression of interferon-alpha response Genes Cancer Research. 76: 4360-4360. DOI: 10.1158/1538-7445.Am2016-4360 |
0.455 |
|
| 2016 |
McKenzie JA, Mbofung RM, Malu S, Amaria RN, Davis RE, Zhang L, Tieu TN, Heffernan TP, Hwu P. Abstract 4002: Enhancing the antitumor efficacy of immunotherapy by using the topoisomerase I inhibitor MM398 Cancer Research. 76: 4002-4002. DOI: 10.1158/1538-7445.Am2016-4002 |
0.494 |
|
| 2016 |
Molina JR, Protopopova M, Bandi M, Bardenhagen J, Bristow C, Carroll C, Chang E, Feng N, Do MG, Greer J, Huang S, Jiang Y, Konopleva M, Matre P, Han J, ... ... Heffernan T, et al. Abstract 335: Title: IACS-010759 is a novel clinical candidate that targets AML cells by inducing a metabolic catastrophe through inhibition of oxidative phosphorylation Cancer Research. 76: 335-335. DOI: 10.1158/1538-7445.Am2016-335 |
0.471 |
|
| 2016 |
Guijarro I, Poteete A, Yang C, Roarty E, Nilsson M, Sun H, Tong P, Chang E, Rodriguez-Canales J, Mino B, Parra E, Wistuba I, Wang J, Heffernan T, Heymach JV. Abstract 3272: LKB1 loss is associated with resistance to VEGF inhibitors in non-small cell lung cancer (NSCLC) Cancer Research. 76: 3272-3272. DOI: 10.1158/1538-7445.Am2016-3272 |
0.48 |
|
| 2016 |
Echeverria GV, Seth S, Cai S, Moulder S, Symmans WF, Heffernan TP, Chang J, Piwnica-Worms H. Abstract 2406: Identifying and targeting chemoresistant subclones in triple negative breast cancer Cancer Research. 76: 2406-2406. DOI: 10.1158/1538-7445.Am2016-2406 |
0.484 |
|
| 2016 |
Wang Z, Malu S, Peng W, McKenzie J, Mbofung R, Williams L, Seth S, Heffernan T, Hwu P. Abstract 1441: Systems-level interrogation of resistance mechanisms to immunotherapy through pooled shRNA screens Cancer Research. 76: 1441-1441. DOI: 10.1158/1538-7445.Am2016-1441 |
0.489 |
|
| 2016 |
Sun Y, Bandi M, Lofton T, Smith M, Bristow C, Rogers N, Edward C, Do MG, Jiang Y, Morlacchi P, Muller F, Mseeh F, Czako B, Palmer W, Toniatti C, ... ... Heffernan T, et al. Abstract 1023: Functional genomics reveals dependency on 6-phosphogluconate dehydrogenase in OXPHOS-deficient tumors Cancer Research. 76: 1023-1023. DOI: 10.1158/1538-7445.Am2016-1023 |
0.36 |
|
| 2015 |
Wang G, Lu X, Dey P, Deng P, Wu CC, Jiang S, Fang Z, Zhao K, Konaparthi R, Hua S, Zhang J, Li-Ning-Tapia EM, Kapoor A, Wu CJ, Patel NB, ... ... Heffernan T, et al. Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression. Cancer Discovery. PMID 26701088 DOI: 10.1186/2051-1426-3-S2-P421 |
0.403 |
|
| 2015 |
Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X, Williams LJ, Deng W, Chen G, Mbofung R, Lazar AJ, ... ... Heffernan TP, et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discovery. PMID 26645196 DOI: 10.1158/2159-8290.Cd-15-0283 |
0.436 |
|
| 2015 |
Rai K, Akdemir KC, Kwong LN, Fiziev P, Wu CJ, Keung EZ, Sharma S, Samant NS, Williams M, Axelrad JB, Shah A, Yang D, Grimm EA, Barton MC, Milton DR, ... Heffernan TP, et al. Dual Roles of RNF2 in Melanoma Progression. Cancer Discovery. PMID 26450788 DOI: 10.1158/2159-8290.Cd-15-0493 |
0.381 |
|
| 2015 |
Vangamudi B, Paul TA, Shah PK, Kost-Alimova M, Nottebaum L, Shi X, Zhan Y, Leo E, Mahadeshwar HS, Protopopov A, Futreal A, Tieu TN, Peoples M, Heffernan TP, Marszalek JR, et al. The SMARCA2/4 ATPase domain surpasses the bromodomain as a drug target in SWI/SNF mutant cancers: Insights from cDNA rescue and PFI-3 inhibitor studies. Cancer Research. PMID 26139243 DOI: 10.1158/0008-5472.Can-14-3798 |
0.444 |
|
| 2015 |
Skoulidis F, Byers LA, Diao L, Papadimitrakopoulou VA, Tong P, Izzo J, Behrens C, Kadara H, Parra ER, Rodriguez Canales J, Zhang J, Giri U, Gudikote J, Cortez MA, Yang C, ... ... Heffernan TP, et al. Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities. Cancer Discovery. PMID 26069186 DOI: 10.1158/2159-8290.Cd-14-1236 |
0.398 |
|
| 2015 |
Colla S, Ong DS, Ogoti Y, Marchesini M, Mistry NA, Clise-Dwyer K, Ang SA, Storti P, Viale A, Giuliani N, Ruisaard K, Ganan Gomez I, Bristow CA, Estecio M, Weksberg DC, ... ... Heffernan TP, et al. Telomere dysfunction drives aberrant hematopoietic differentiation and myelodysplastic syndrome. Cancer Cell. 27: 644-57. PMID 25965571 DOI: 10.1016/J.Ccell.2015.04.007 |
0.356 |
|
| 2015 |
Pettazzoni P, Viale A, Shah P, Carugo A, Ying H, Wang H, Genovese G, Seth S, Minelli R, Green T, Huang-Hobbs E, Corti D, Sanchez N, Nezi L, Marchesini M, ... ... Heffernan TP, et al. Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer. Cancer Research. 75: 1091-101. PMID 25736685 DOI: 10.1158/0008-5472.Can-14-1854 |
0.452 |
|
| 2015 |
Viale A, Pettazzoni P, Lyssiotis C, Ying H, Sánchez N, Marchesini M, Carugo A, Green T, Seth S, Giuliani V, Heffernan T, Kimmelman A, Wang H, Fleming J, Cantley L, et al. Abstract PR13: Pancreatic tumor stem cells resistant to inhibition of oncogenic signaling are dependent on mitochondrial function Cancer Research. 75. DOI: 10.1158/1538-7445.Panca2014-Pr13 |
0.477 |
|
| 2015 |
Kapoor A, Yao W, Ying H, Hua S, Liewen A, Sadanandam A, Al-Khalil R, Viale A, Pettazzoni P, Sanchez N, Protopopov A, Zhang J, Heffernan T, Johnson RL, Chin L, et al. Abstract A94: Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Panca2014-A94 |
0.483 |
|
| 2015 |
Corti D, Carugo A, Sahil S, Marchesini M, Pettazzoni P, Nezi L, Green T, Marszalek JR, Francesco MED, Heffernan TP, Draetta GF, Viale A. Abstract 976: Metabolic eradication of treatment resistant cancer stem cells in pancreatic tumors: A clonal tracking-based platform for identifying the best personalized treatment Cancer Research. 75: 976-976. DOI: 10.1158/1538-7445.Am2015-976 |
0.465 |
|
| 2015 |
Skoulidis F, Byers L, Diao L, Papadimitrakopoulou V, Tong P, Izzo J, Behrens C, Kadara H, Parra ER, Rodriguez-Canales J, Zhang J, Giri U, Gudikote J, Cortez MA, Yang C, ... ... Heffernan TP, et al. Abstract 968: Co-occurring genomic alterations define major subsets ofKRAS-mutant lung adenocarcinoma (LUAC) with distinct biology and therapeutic vulnerabilities Cancer Research. 75: 968-968. DOI: 10.1158/1538-7445.Am2015-968 |
0.463 |
|
| 2015 |
Wang Q, Ezhilarasan R, Goodman LD, Gumin J, Zheng S, Yoshihara K, Sun P, Yang J, Heffernan T, Draetta G, Aldape KD, Lang FF, Verhaak RGW, Sulman EP. Abstract 4795: A novel gene fusion in glioblastoma and a radiation response methylation signature identified by genomic characterization of glioma sphere-forming cells Cancer Research. 75: 4795-4795. DOI: 10.1158/1538-7445.Am2015-4795 |
0.472 |
|
| 2015 |
Vangamudi B, Paul T, Shah PK, Alimova MK, Nottebaum L, Shi X, Zhan Y, Leo E, Mahadeshwar HS, Protopopov A, Futreal A, Tieu TN, Peoples M, Petrocchi A, Marszalek JR, ... ... Heffernan TP, et al. Abstract 3528: The SMARCA2/4 catalytic activity, but not the bromodomain, is a drug target in SWI/SNF mutant cancers Cancer Research. 75: 3528-3528. DOI: 10.1158/1538-7445.Am2015-3528 |
0.45 |
|
| 2015 |
Carugo A, Genovese G, Seth S, Nezi L, Rose JL, Viale A, Pettazzoni PF, Cicalese A, Bossi D, Yao W, Fleming JB, Lanfrancone L, Heffernan TP, Draetta GF. Abstract 1701: Identification of epigenetic modifiers able to suppress growth of pancreatic ductal adenocarcinoma: A patient-orientedin vivofunctional platform Cancer Research. 75: 1701-1701. DOI: 10.1158/1538-7445.Am2015-1701 |
0.439 |
|
| 2015 |
Wang Q, Eskilsson E, Ezhilarasan R, Zheng S, Gumin J, Heffernan T, Draetta G, Lang F, Verhaak R, Sulman E. Geno-36Glioma Sphere-Forming Cells Reveal Intrinsic Global Hypermethylation Associated With Gbm Radiation Resistance Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov215.36 |
0.3 |
|
| 2014 |
Viale A, Pettazzoni P, Lyssiotis CA, Ying H, Sánchez N, Marchesini M, Carugo A, Green T, Seth S, Giuliani V, Kost-Alimova M, Muller F, Colla S, Nezi L, Genovese G, ... ... Heffernan TP, et al. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature. 514: 628-32. PMID 25119024 DOI: 10.1038/Nature13611 |
0.413 |
|
| 2014 |
Kapoor A, Yao W, Ying H, Hua S, Liewen A, Wang Q, Zhong Y, Wu CJ, Sadanandam A, Hu B, Chang Q, Chu GC, Al-Khalil R, Jiang S, Xia H, ... ... Heffernan T, et al. Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Cell. 158: 185-97. PMID 24954535 DOI: 10.1016/J.Cell.2014.06.003 |
0.459 |
|
| 2014 |
Wardwell-Ozgo J, Dogruluk T, Gifford A, Zhang Y, Heffernan TP, van Doorn R, Creighton CJ, Chin L, Scott KL. HOXA1 drives melanoma tumor growth and metastasis and elicits an invasion gene expression signature that prognosticates clinical outcome. Oncogene. 33: 1017-26. PMID 23435427 DOI: 10.1038/Onc.2013.30 |
0.337 |
|
| 2014 |
Kapoor A, Yao W, Ying H, Hua S, Liewen A, Wang Q, Zhong Y, Wu C, Sadanandam A, Hu B, Chang Q, Chu G, Al-Khalil R, Jiang S, Xia H, ... ... Heffernan T, et al. Abstract PR01: Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer Molecular Cancer Research. 12. DOI: 10.1158/1557-3125.Rasonc14-Pr01 |
0.48 |
|
| 2014 |
Smith PG, Sutton D, Bertotti A, Trusolino L, Airhart S, Tsao MS, Wouters BG, Eckhardt SG, Wang L, Heffernan T, Verbel D, Gerken A, Fekkes P, Yu L, Warmuth M. Abstract 1191: Translational Proof-of-Concept (TransPoC), a not-for-profit research organization enabling access to large-scale translational oncology platforms: The Patient-Derived Xenograft network Cancer Research. 74: 1191-1191. DOI: 10.1158/1538-7445.Am2014-1191 |
0.395 |
|
| 2014 |
Wang Q, Ezhilarasan R, Zheng S, Gumin J, Heffernan T, Draetta G, Lang F, Verhaak R, Sulman E. Ge-39Validation Of Glioma Sphere-Forming Cells As Models Of Glioblastoma And Identification Of Novel Drivers Of Tumorigenesis Through Comprehensive Genomic Characterization Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou256.38 |
0.45 |
|
| 2014 |
Wang Q, Ezhilarasan R, Zheng S, Gumin J, Heffernan T, Draetta G, Lang F, Verhaak R, Sulman E. Ge-38Identifying The Treatment-Resistant Mesenchymal Signature By Comparative Analyses Between Glioma Sphere-Forming Cells And Their Glioblastomas Of Origin Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou256.37 |
0.425 |
|
| 2014 |
Sulman EP, Wang Q, Ezhilarasan R, Goodman LD, Gumen J, Sun P, Aldape K, Yung WA, Heffernan T, Draetta GF, Lang FF. The Treatment-Resistant Mesenchymal Signature In Glioblastoma Derives From Tumor Cells Independent Of Stroma Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou206.28 |
0.434 |
|
| 2012 |
Berger MF, Hodis E, Heffernan TP, Deribe YL, Lawrence MS, Protopopov A, Ivanova E, Watson IR, Nickerson E, Ghosh P, Zhang H, Zeid R, Ren X, Cibulskis K, Sivachenko AY, et al. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature. 485: 502-6. PMID 22622578 DOI: 10.1038/Nature11071 |
0.347 |
|
| 2011 |
Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, Chesi M, Schinzel AC, McKeown MR, Heffernan TP, Vakoc CR, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 146: 904-17. PMID 21889194 DOI: 10.1016/J.Cell.2011.08.017 |
0.385 |
|
| 2011 |
Kawasumi M, Lemos B, Bradner JE, Thibodeau R, Kim YS, Schmidt M, Higgins E, Koo SW, Angle-Zahn A, Chen A, Levine D, Nguyen L, Heffernan TP, Longo I, Mandinova A, et al. Protection from UV-induced skin carcinogenesis by genetic inhibition of the ataxia telangiectasia and Rad3-related (ATR) kinase. Proceedings of the National Academy of Sciences of the United States of America. 108: 13716-21. PMID 21844338 DOI: 10.1073/Pnas.1111378108 |
0.448 |
|
| 2011 |
Scott KL, Nogueira C, Heffernan TP, van Doorn R, Dhakal S, Hanna JA, Min C, Jaskelioff M, Xiao Y, Wu CJ, Cameron LA, Perry SR, Zeid R, Feinberg T, Kim M, et al. Proinvasion metastasis drivers in early-stage melanoma are oncogenes. Cancer Cell. 20: 92-103. PMID 21741599 DOI: 10.1016/J.Ccr.2011.05.025 |
0.399 |
|
| 2009 |
Heffernan TP, Kawasumi M, Blasina A, Anderes K, Conney AH, Nghiem P. ATR-Chk1 pathway inhibition promotes apoptosis after UV treatment in primary human keratinocytes: potential basis for the UV protective effects of caffeine. The Journal of Investigative Dermatology. 129: 1805-15. PMID 19242509 DOI: 10.1038/Jid.2008.435 |
0.413 |
|
| 2008 |
Wiedemeyer R, Brennan C, Heffernan TP, Xiao Y, Mahoney J, Protopopov A, Zheng H, Bignell G, Furnari F, Cavenee WK, Hahn WC, Ichimura K, Collins VP, Chu GC, Stratton MR, et al. Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development. Cancer Cell. 13: 355-64. PMID 18394558 DOI: 10.1016/J.Ccr.2008.02.010 |
0.359 |
|
| 2007 |
Heffernan TP, Unsal-Kaçmaz K, Heinloth AN, Simpson DA, Paules RS, Sancar A, Cordeiro-Stone M, Kaufmann WK. Cdc7-Dbf4 and the human S checkpoint response to UVC. The Journal of Biological Chemistry. 282: 9458-68. PMID 17276990 DOI: 10.1074/Jbc.M611292200 |
0.618 |
|
| 2006 |
Chastain PD, Heffernan TP, Nevis KR, Lin L, Kaufmann WK, Kaufman DG, Cordeiro-Stone M. Checkpoint regulation of replication dynamics in UV-irradiated human cells. Cell Cycle (Georgetown, Tex.). 5: 2160-7. PMID 16969085 DOI: 10.4161/Cc.5.18.3236 |
0.614 |
|
| 2005 |
Simpson DA, Livanos E, Heffernan TP, Kaufmann WK. Telomerase expression is sufficient for chromosomal integrity in cells lacking p53 dependent G1 checkpoint function. Journal of Carcinogenesis. 4: 18. PMID 16209708 DOI: 10.1186/1477-3163-4-18 |
0.603 |
|
| 2005 |
King NM, Nikolaishvili-Feinberg N, Bryant MF, Luche DD, Heffernan TP, Simpson DA, Hanaoka F, Kaufmann WK, Cordeiro-Stone M. Overproduction of DNA polymerase eta does not raise the spontaneous mutation rate in diploid human fibroblasts. Dna Repair. 4: 714-24. PMID 15886068 DOI: 10.1016/J.Dnarep.2005.04.002 |
0.613 |
|
| 2003 |
Kaufmann WK, Heffernan TP, Beaulieu LM, Doherty S, Frank AR, Zhou Y, Bryant MF, Zhou T, Luche DD, Nikolaishvili-Feinberg N, Simpson DA, Cordeiro-Stone M. Caffeine and human DNA metabolism: the magic and the mystery. Mutation Research. 532: 85-102. PMID 14643431 DOI: 10.1016/J.Mrfmmm.2003.08.012 |
0.614 |
|
| 2002 |
Heffernan TP, Simpson DA, Frank AR, Heinloth AN, Paules RS, Cordeiro-Stone M, Kaufmann WK. An ATR- and Chk1-dependent S checkpoint inhibits replicon initiation following UVC-induced DNA damage. Molecular and Cellular Biology. 22: 8552-61. PMID 12446774 DOI: 10.1128/Mcb.22.24.8552-8561.2002 |
0.629 |
|
| Show low-probability matches. |